Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

October 5, 2025

Study Completion Date

October 12, 2025

Conditions
Diabetic Foot Ulcer
Interventions
BIOLOGICAL

PEP (Purified Exosome Product) / TISSEEL

"PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies"

Trial Locations (1)

45242

Professional Education & Research Institute (PERI), Blue Ash

All Listed Sponsors
collaborator

Professional Education and Research Institute

OTHER

lead

Rion Inc.

INDUSTRY